Wordt geladen...
Early Tolerability and Safety of Fingolimod in Clinical Practice
BACKGROUND: Fingolimod is approved by the U.S. Food and Drug Administration to reduce relapses and disability progression in relapsing forms of MS. Several screening studies and a first-dose observation (FDO) period are recommended due to adverse effects observed in clinical trials. OBJECTIVE: To de...
Bewaard in:
Hoofdauteurs: | , , , , |
---|---|
Formaat: | Artigo |
Taal: | Inglês |
Gepubliceerd in: |
2012
|
Onderwerpen: | |
Online toegang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3970706/ https://ncbi.nlm.nih.gov/pubmed/23040960 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jns.2012.09.009 |
Tags: |
Voeg label toe
Geen labels, Wees de eerste die dit record labelt!
|